Occentis is a drug discovery and development company, focusing on mental health, with a groundbreaking approach backed by over two decades of extensive research conducted at the renowned French National Center for Scientific Research (CNRS) under the guidance of Professor Marcel Hibert, a distinguished figure in medicinal chemistry. Our mission is to revolutionise the treatment landscape for neuropsychiatric and neurobehavioral conditions, addressing significant unmet needs in therapeutic areas such as Autism, Alcohol and Opioid addiction, Pain and other conditions. In close collaboration with Conectus, a leading technology transfer and innovation organization working with the CNRS, Occentis has exclusively licensed this remarkable research. Conectus, known for its expertise in bridging the gap between academia and industry, played a pivotal role in this partnership. Together with the CNRS and Professor HIBERT, Occentis is aiming to address critical unmet needs in mental health.
Company Details
- Address
- 5, Rue Schiller, Strasbourg,grand Est 67000,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://occentis.com/
- HQ
- Strasbourg, Grand Est
Occentis Questions
Occentis's website is https://occentis.com/
Occentis's LinkedIn profile is https://fr.linkedin.com/company/occentis
Occentis's industry is
Biotechnology Research
Occentis's top competitors are
Make Open Data,
Qaelon Medical,
Serendip Innovations,
Institut Clinique De La Souris Ics,
Neurentis Plc,
Brightsens Diagnostics,
Futuroleaf,
Albupad,
Asaria - Assisted Surgery By Augmented Reality & Ia,
Noviga.
Occentis's categories are Biotechnology Research
